Anavex Life Sciences Names Terrie Kellmeyer CEO as AVXL Navigates Clinical and Market Challenges

Anavex appoints Terrie Kellmeyer as permanent CEO By Investing.com

Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors

Aevex stock drops 5% as US Navy halts $130M drone boat program

Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies

Anavex Life Sciences Completes Clinical Conduct Of Drug-Drug Interaction, Absorption, Distribution, Metabolism And Excretion Trials Of Blarcamesine; Receives FDA Clearance For Its Investigational New Drug Application In Fragile X Syndrome; To Meet With FDA To Discuss Inclusion Of Participants In Its Phase 3 Rett Syndrome Trial

Anavex: Downgrading To Sell On Blarcamesine MAA Withdrawal For AD, Pipeline Change

Anavex Receives FDA IND Clearance for Blarcamesine in Fragile X Syndrome, Enabling Phase 2a Trial

Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome

Anavex Life Sciences Receives FDA Clearance to Proceed Ahead With Its Planned Clinical Trial Under Its Investigational New Drug Application For ANAVEX 2-73 For Fragile X Syndrome

Fragile X has no FDA-approved treatment. Anavex plans a study in about 60 adult men.

Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting

PVG Asset Management Announces Plan for First 100 Days at Anavex Life Sciences

PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance

PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign